Thelansis’s “Metastatic ER+/HER2- Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Metastatic ER+/HER2- breast cancer is the most common form of advanced disease we manage, and while it generally moves slower than other subtypes, the clinical challenge lies in its ability to eventually outsmart our treatments. At its core, the cancer is fueled by estrogen, but over time, the tumor cells mutate—specifically at the ESR1 or PIK3CA genes—to bypass the very therapies meant to stop them. For years, we relied solely on hormone blockers, but the real breakthrough has been the introduction of CDK4/6 inhibitors. These drugs have fundamentally changed the outlook for these patients by hitting the cell cycle directly, significantly pushing back the need for aggressive chemotherapy. The current frontline strategy is a high-stakes balancing act: we aim to keep the disease under control using targeted oral therapies for as long as possible, only pivoting to newer options like antibody-drug conjugates when the cancer finally develops resistance. Even with these advancements, the “unmet need” remains the same—finding a way to permanently break that resistance without compromising the patient’s day-to-day quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Metastatic ER+/HER2- Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report
Our team will get in touch with you shortly about the Metastatic ER+/HER2- Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report.